Acute Ischemic Stroke
Conditions
Keywords
TNK-tPA, rt-PA, Acute stroke, phase Ⅲ trial
Brief summary
The trial is prospective, randomized, open-label, blinded endpoint (PROBE) design. Patients with acute ischemic stroke, who are eligible for standard intravenous thrombolysis within 4.5 hours of stroke onset will be randomized 1:1 to 0.25mg/kg or 0.9 mg/kg alteplase before all participants undergo endovascular thrombectomy.
Detailed description
The study will be a multi-center, prospective, randomized, open- label, blinded endpoint (PROBE), controlled phase 3 trial (2 arm with 1:1 randomization) in ischemic stroke patients. Imagine is performed with CT or MRI acutely with imaging follow-up at 24-36 hours. The sample size is 1630.
Interventions
DRUGAlteplase
Alteplase 0.9mg/kg are being used.
DRUGTenecteplase
Tenecteplase 0.25mg/kg are being used.
Sponsors
Jiangsu FENG HUA Biotech Pharmaceutical Co., Ltd
The Place Pharmaceutical(Jiangsu) Co., Ltd
Beijing Tiantan Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* 18≤Age≤80 years old; * The clinical diagnosis was Acute ischemic stroke The time from onset to treatment was \< 4.5h; The time at which symptoms begin is defined as the time at which they finally appear normal; * MRS before onset was ≤1 points; * Baseline NIHSS (at the time of randomization) should be ≥5 and ≤25 points; * Informed consent from the patient or surrogate.
Exclusion criteria
* Intracranial hemorrhage identified by CT or MRI (CMBs detected by SWI is not counted); * Massive anterior cerebral infarction identified by CT or MRI (ASPECT \< 6 or lesions larger than one third of the territory of the middle cerebral artery or with a volume larger than 70mL) * Patients planning to receive endovascular therapy * A history of severe CNS damage (such as aneurysm or arteriovenous malformation, craniocerebral trauma, intracranial or spinal cord surgery) * Onset with seizures, and the paralysis was suspected to be related to Todd paralysis. * Administration of heparin within 48 hours preceding the onset of stroke with a baseline APTT exceeding the upper limit of the normal range. * Oral anticoagulant (such as warfarin) treatment with baseline INR\>1.7 or PT\>15 s; * Administration of thrombin inhibitors or factor Xa inhibitors within 48 hours preceding the onset of stroke with abnormal coagulation parameters or platelet count; * BP couldn't be controlled with aggressive treatment. Uncontrolled hypertension was defined as systolic blood pressure \>185 mmHg or diastolic blood pressure \>110 mmHg, measured for three times every 10 minutes. * Platelet count of less than 100×109/ L; * Blood glucose \<50 mg/dl (\<2.8 mmol/L) or \>400 mg/dl (22.22 mmol/L); * History of intracranial hemorrhage or active hemorrhagic disease. (Such as gastrointestinal, urinary tract or retinal bleeding) * Tumors with an increased risk of bleeding. * Prolonged or traumatic cardiopulmonary resuscitation (\>2 min), delivery within the last 10 days or recent puncture of non-compression vessels such as subclavian vein or jugular vein * Acute pancreatitis or severe liver disease, including liver failure, cirrhosis, portal hypertension, esophageal varicose veins, and active hepatitis; * Aortic arch dissection; * Major surgery or severe trauma in the past 2 weeks; * Subjects had serious, fatal, or disabling disease with an expected survival of less than 3 months; * Unable to complete neurological assessment and follow-up visits because of dementia or mental illness; * Pregnant women, lactating women, or have positive pregnancy test; * Allergy to tenecteplase or alteplase or their components; * Participation in other clinical trials within 3 months prior to screening; * Unsuitable to involve in this study or would result in increased risk, as judged by the investigators.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Modified Rankin Scale(mRS) | 90±7 days | Proportion of subjects with mRS scores of (0-1) at 90±7 days. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| National Institutes of Health Stroke Scale (NIHSS) | 24±2 hours | NIHSS score at 24±2 hours. |
| Modified Rankin Scale(mRS) | 90±7 days | Proportion of subjects with mRS scores of (0-2) at 90±7 days. |
| The new vascular events | 90±7 days | Incidence of the new vascular events, ischemic stroke, hemorrhagic stroke, myocardial infarction and cardio-cerebral revascularization at 90±7 days. (including: carotid endarterectomy, intracranial and extracranial artery interventional therapy, intracranial and extracranial artery bypass surgery, coronary interventional or bypass therapy) |
| EQ-5D | 90±7 days | EQ-5D scores at 90±7 days. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Any intracranial hemorrhage | 24~36 hours post treatment | Incidence of any intracranial hemorrhage within 24\ 36 hours. |
| Systematic bleeding | 36 hours | Incidence of Systematic bleeding within 36 hours. (defined by GUSTO) |
| Symptomatic intracranial hemorrhage(sICH) | 24~36 hours post treatment | Incidence of symptomatic intracranial hemorrhage (sICH) within 24\ 36 hours.( According to ECASS Ⅲ and SITS-MOST) |
| Deaths | 90±7 days | Vascular mortality at 90±7 days (mainly due to stroke, myocardial infarction or pulmonary embolism) |
| SAEs | 90±7 days | Incidence of severe adverse events(SAEs) at 90±7 days. |
| AEs | 90±7 days | Incidence of adverse events(AEs) at 90±7 days. |
| Parenchymal hematoma intracranial hemorrhage (type PH2, SITS-MOST) | 24~36 hours post treatment | Incidence of intracranial hemorrhage (type PH2, SITS-MOST) within 24\ 36 hours. |
Countries
China
Contacts
Primary ContactYongjun Wang
Backup ContactShuya Li
Outcome results
None listed